MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) said it will host a corporate update webinar later this month as the clinical-stage biotechnology company moves into what it describes as a milestone-rich period for its neurological disease programs.
The webinar is scheduled for Wednesday, January 28, 2026, at 4:30 p.m. Eastern and will be led by President and Chief Executive Officer Maria Maccecchini. The presentation will outline recent company progress, provide updates on ongoing clinical studies, and discuss Annovis’s strategic direction.
Annovis is focused on developing therapies for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease, areas where effective treatments remain limited and competition for breakthrough therapies is intense. Management has pointed to advancing clinical data and corporate execution as key drivers of momentum heading into 2026.
Following the presentation, the company will hold a live question-and-answer session. The event is open to shareholders, patients, investigators, and other interested participants.
Annovis is headquartered in Malvern, Pennsylvania, and continues to position its research programs around the goal of slowing or halting neurodegeneration, a challenge that remains one of the most pressing and costly in global healthcare.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.